This application is the competitive renewal application of NIH MH-42088, seeking five years of support, which would represent years 15-19 of this project on the Psychobiology of Corticotropin-Releasing Factor (CRF). In the past years, this grant has provided much evidence for a preeminent role for CRF-containing neurons in mediating the response, characterized in considerable detail the neurotransrnitter role of CRF in the mammalian CNS, and perhaps most importantly, contributed to the burgeoning dah base which supports the hypothesis that CRF is hypersecreted in patients with major depression. Indeed, contributions from this and other laboratories using a variety of multidisciplinary approaches have provided unequivocal evidence for hyperactivity of CRF-containing in neurons patients with major depression, particularly those patients with severe depression. The current proposal seeks to extend this work in directions largely based upon findings obtained during the current funding period (aims I & 2 in a new direction as well (genetics aims 3 & 4). Specifically, the investigators wish to continue the postmortem brain tissue studies to further characterize that alterations in CRF-containing neurons and CRF receptor-containing neurons by scrutinizing CRF and CRF receptor mRNA expression, as well as focusing on the CRF2 receptor and urocortin The development of small molecule, non-peptide CRF1 receptor antagonists has occurred to some extent due to the investigators progress in this field. With their increasing availability, the behavioral, endocrine, and neurochemical responses chronic administration of these CRF1 receptor antagonists will be characterized. Moreover, the responses to discontinuation of these compounds will be assessed. In a novel animal model of depression based upon sensitivity stress in the forced-swim test that is highly sensitive to all classes of antidepressants, the investigators will determine whether CRF1 receptor antagonists exhibit an antidepressant profile. Moreover, are alterations in CNS CRF neuronal systems and receptors present in this animal model? Because evidence suggests that altered CRF function appears to be responsible, at least in part, for the anxiety and/or depression phenotype in some animal models, the investigators will map the quantitative trait loci (QTL) that control the expression of the CRF system. These studies will provide novel information on the role of CRF nepronal systems in the pathophysiology of depression, in animal models of systemic CRF1 receptor antagonist administration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH042088-16
Application #
6499231
Study Section
Special Emphasis Panel (ZRG1-BDCN-6 (01))
Program Officer
Winsky, Lois M
Project Start
1991-09-01
Project End
2005-01-31
Budget Start
2002-04-17
Budget End
2003-01-31
Support Year
16
Fiscal Year
2002
Total Cost
$380,000
Indirect Cost
Name
Emory University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Flandreau, Elizabeth I; Ressler, Kerry J; Owens, Michael J et al. (2012) Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus. Psychoneuroendocrinology 37:27-38
Pariante, Carmine M; Nemeroff, Charles B (2012) Unipolar depression. Handb Clin Neurol 106:239-49
Hanson, Nicola D; Nemeroff, Charles B; Owens, Michael J (2011) Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus. J Pharmacol Exp Ther 337:180-6
Hanson, Nicola D; Owens, Michael J; Boss-Williams, Katherine A et al. (2011) Several stressors fail to reduce adult hippocampal neurogenesis. Psychoneuroendocrinology 36:1520-9
Bonne, Omer; Gill, Jessica Mary; Luckenbaugh, David A et al. (2011) Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry 72:1124-8
Gutman, David A; Owens, Michael J; Thrivikraman, K V et al. (2011) Persistent anxiolytic affects after chronic administration of the CRFýýý receptor antagonist R121919 in rats. Neuropharmacology 60:1135-41
Coplan, Jeremy D; Abdallah, Chadi G; Kaufman, Joan et al. (2011) Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: a pilot study. Psychoneuroendocrinology 36:289-93
Martin, Elizabeth I; Ressler, Kerry J; Binder, Elisabeth et al. (2010) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Clin Lab Med 30:865-91
Binder, E B; Nemeroff, C B (2010) The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15:574-88
Martin, Elizabeth I; Ressler, Kerry J; Jasnow, Aaron M et al. (2010) A novel transgenic mouse for gene-targeting within cells that express corticotropin-releasing factor. Biol Psychiatry 67:1212-6

Showing the most recent 10 out of 176 publications